(c) 2024 PillSync.com

Rosuvastatin calcium 5 MG Oral Tablet

1 INDICATIONS AND USAGE Rosuvastatin tablets are indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥ 2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. Reduce LDL-C and slow the progression of atherosclerosis in adults. Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia. Rosuvastatin tablets are an HMG Co-A reductase inhibitor (statin) indicated: ( 1 ) To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥ 2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: reduce LDL-C in adults with primary hyperlipidemia. reduce LDL-C and slow the progression of atherosclerosis in adults. reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia.

Amneal Pharmaceuticals NY LLC


4 years ago ROUND YELLOW AA 92 Rosuvastatin calcium 5 MG Oral Tablet

ROUND YELLOW AA 92

16 HOW SUPPLIED/STORAGE AND HANDLING

ROSUVASTATIN Tablets USP, 5 mg are supplied as yellow colored, round, biconvex, coated tablets, debossed “AA†and “92†on one side and plain on the other side. They are available as follows: Bottles of 90: NDC 69238-1146-9

ROSUVASTATIN Tablets USP, 10 mg are supplied as pink colored, round, biconvex, coated tablets, debossed “AA†and “93†on one side and plain on the other side. They are available as follows: Bottles of 90: NDC 69238-1147-9

ROSUVASTATIN Tablets USP, 20 mg are supplied as pink colored, round, biconvex, coated tablets, debossed “AA†and “94†on one side and plain on the other side. They are available as follows: Bottles of 90: NDC 69238-1148-9

ROSUVASTATIN Tablets USP, 40 mg are supplied as pink colored, oval, biconvex, coated tablets, debossed “AA 95†on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 69238-1149-3 Bottles of 90: NDC 69238-1149-9 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.


More pills like ROUND AA 92

Related Pills

Rosuvastatin calcium 40 MG Oral Tablet

Amneal Pharmaceuticals NY LLC

Rosuvastatin calcium 20 MG Oral Tablet

Amneal Pharmaceuticals NY LLC

Rosuvastatin calcium 10 MG Oral Tablet

Amneal Pharmaceuticals NY LLC












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site